id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15201 R62354 |
Cohen (Valproate) (Mixed indications) (Controls unexposed, NOS), 2023 | Hypospadias | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 6.47 [4.32;9.69] | -/2,031 -/4,866,362 | - | 2,031 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10174 R37217 |
Blotière (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
3.78 [1.37;10.44] C excluded (control group) |
8/913 7/2,997 | 15 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10051 R36491 |
Blotière (Valproate) (Controls unexposed NOS) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 4.80 [2.40;9.80] | 8/913 3,371/1,875,733 | 3,379 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9359 R32736 |
Tomson (Valproate), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 6.77 [2.74;16.73] C | 22/1,381 6/2,514 | 28 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9333 R32557 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Hypospadias and genitourinary tract defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.60 [1.16;5.81] | 15/1,220 10/2,098 | 25 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32514 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Hypospadias | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.52 [0.63;10.13] C excluded (control group) |
4/333 4/833 | 8 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9326 R32521 |
Veiby (Valproate) (Controls unexposed, disease free) (Mixed indications), 2014 | Hypospadias | throughout pregnancy | population based cohort retrospective | unexposed, disease free | Adjustment: Yes | 5.71 [2.13;15.30] | 4/333 1,543/771,412 | 1,547 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9309 R32428 |
Källén (Valproate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Hypospadias | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
10.65 [3.15;35.96] C excluded (control group) |
20/697 3/1,084 | 23 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9310 R32436 |
Källén (Valproate) (Controls unexposed, NOS) (Indications NOS), 2013 | Hypospadias | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 7.33 [4.48;11.30] | 20/697 4,552/1,575,847 | 4,572 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10231 R37481 |
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 54.10 [2.98;980.87] C | 5/323 0/1,562 | 5 | 323 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9331 R32552 |
Bànhidy (Valproate), 2011 | Hypospadias | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 2.00 [0.29;13.74] C | 3/8 3/13 | 6 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9444 R33168 |
Diav-Citrin (Valproate) (Mixed indications), 2008 | Hypospadias | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 4.40 [0.49;39.89] C | 1/71 4/1,236 | 5 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9297 R32306 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9298 R32335 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 10 studies | 5.88 [4.60;7.51] | 9,567 | 6,978 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Mixed indications) (Controls unexposed, NOS; 2: Valproate) (Controls unexposed NOS) (Mixed indications; 3: Valproate; 4: Valproate) (Controls exposed to Lamotrigine, sick; 5: Valproate) (Controls unexposed, disease free) (Mixed indications; 6: Valproate) (Controls unexposed, NOS) (Indications NOS; 7: Valproate) (Controls exposed to Lamotrigine, sick; 8: Valproate; 9: Valproate) (Mixed indications; 10: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.8201 (by Egger's regression)
slope=1.8204 (0.2363); intercept=-0.1429 (0.6082); t=0.2350; p=0.8201
excluded 9297, 9309, 9325, 10174